{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:15:36Z","timestamp":1761894936527},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,16]]},"DOI":"10.1093\/jnci\/djp255","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T02:16:36Z","timestamp":1250561796000},"page":"1287-1288","source":"Crossref","is-referenced-by-count":2,"title":["Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials"],"prefix":"10.1093","volume":"101","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"issue":"4","key":"key\n\t\t\t\t20170702094512_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"key\n\t\t\t\t20170702094512_bib2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"key\n\t\t\t\t20170702094512_bib3","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"10","key":"key\n\t\t\t\t20170702094512_bib4","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"13","key":"key\n\t\t\t\t20170702094512_bib5","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"10","key":"key\n\t\t\t\t20170702094512_bib6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18S","key":"key\n\t\t\t\t20170702094512_bib7","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","article-title":"Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG\/CALGB intergroup E1496 trial [2007 ASCO Annual Meeting Proceedings Part I]","volume":"25","author":"Hochster","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/101\/18\/1287\/18084886\/djp255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T13:52:57Z","timestamp":1590069177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djp255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":7,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2009,9,16]]},"published-print":{"date-parts":[[2009,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djp255","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,16]]}}}